 RICHMOND, Calif., Feb. 08, 2021 GLOBE NEWSWIRE -- Ekso Bionics Holdings, Inc. Nasdaq: EKSO Ekso Bionics, an industry leader in exoskeleton technology for medical and industrial use, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 3,902,440 shares of common stock of Ekso Bionics, at a price to the public of 10.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 11, 2021, subject to the satisfaction of customary closing conditions. 